Our Technology
We found that the bacterial strain Lactobacillus paracasei ICVB411 (lactic acid bacteria, LAB) from a traditional soft cheese is capable of producing five novel bacteriocins.
These novel bacteriocins were synthesized and found in the culture supernatant. They were partially purified and successfully tested against a panel of E. coli strains, including Escherichia coli (E. coli) carrying the 25 mcr-1 gene. The data presented here underscore the potential of LAB-bacteriocins as molecules potentially useful in the treatment of colibacillosis infections in pigs, particularly in piglets. In addition, the formulation of the bacteriocins with biocompatible alginate nanoparticles allowed to improve their antibacterial efficacy by lowering the minimum inhibition concentration (MIC).
​
The development of antibiotic molecules to control emerging infections caused by Gram-negative bacteria (GNB) such as E. coli is a major concern in both human and veterinary medicine. Our invention addresses this challenge by:
​
-
A new lactic acid bacterial strain capable of producing five antibacterial/antimicrobial peptides of a proteinaceous nature, consistent with the bacteriocin qualification,
-
New antibacterial/antimicrobial compounds are active against GNB strains and in particular against E. coli strains,
​
-
New compounds that can be used in combination with colistin to reduce the amount of colistin administered or to increase the antibacterial activity of colistin,
​
-
New antibacterial compounds effective against colistin-resistant strains and in particular colistin-resistant E. coli strains,
​
-
a formulation of an active pharmaceutical composition and, moreover, a pharmaceutical having a non-pH-dependent activity,
​
-
a pharmaceutical composition or new antibacterial/antimicrobial compounds that have a low probability of developing bacterial resistance